{
  "pmcid": "11930396",
  "sha256": "ebda5ad3c49f212106ec186dbeb55e4f785456e6bd751572174fd9b495115b95",
  "timestamp_utc": "2025-11-09T23:23:13.320214+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.005047071129706,
    "reading_ease": 33.8988397838215,
    "word_count": 239
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Recombinant Factor VIIa for Bleeding Prevention and Treatment"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised to receive either rFVIIa or placebo."
      },
      "Participants": {
        "score": 0,
        "evidence": "The study setting and participant eligibility criteria were not detailed."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to receive either rFVIIa or placebo."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates its effectiveness in such contexts."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcome was mortality, with secondary outcomes including blood loss, red cell transfusion requirements, and thromboembolic events."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and allocation concealment methods were not specified."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding involved patients, clinicians, and outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 4290 participants were randomised, with 2607 receiving rFVIIa."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Analysis was conducted using an unspecified approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Prophylactic use in 1361 participants showed no mortality benefit (RR 1.04; 95% CI 0.55 to 1.97) but reduced blood loss (MD -297 mL; 95% CI -416 to -178) and transfusion needs (MD -261 mL; 95% CI -367 to -154)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Increased thromboembolic events were noted (RR 1.45; 95% CI 1.02 to 2.05)."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: Not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 14,
    "max_score": 25
  }
}